As artificial intelligence and machine learning continue to reshape the landscape of drug discovery, this panel will tackle one of the field’s most pressing questions: how do we separate real innovation from overpromised potential?
Inductive Bio’s Josh Haimson, Co-founder & CEO, will be hosting the following session at ACS Fall 2024.
Sifting Reality from Hype – AI and ML in Drug Discovery
- Tuesday, August 20, 12:00 – 1:35 PM
- Colorado Convention Center | Four Seasons Ballroom 1
Josh will be joined by a distinguished panel of experts who bring deep experience from across the industry:
- Elizabeth Joshi - Eli Lilly and Company
- Maria-Jesus Blanco - Atavistik Bio
- Katerina Leftheris
- David Kombo - Sanofi
Together, they’ll explore what’s working, what’s not, and what’s next for AI-driven drug development.
Want to meet with Inductive Bio at ACS Fall? Book a meeting here.
Inductive Bio Raises $25M Series A to Transform Small Molecule Drug Discovery with Industry-Wide AI Platform
Funding will accelerate company’s work to democratize state-of-the-art AI models trained on a pre-competitive dataset to speed the successful development of life-saving therapies
Funding will accelerate company’s work to democratize state-of-the-art AI models trained on a pre-competitive dataset to speed the successful development of life-saving therapies
Inductive Bio to Present at ACS Spring 2025 on the Future of AI in Drug Discovery
The rapid rise of AI in drug discovery brings both unprecedented opportunities and complex challenges. From accelerating the development of better therapies to navigating the proliferation of tools and technologies, the path forward requires clarity, precision, and innovation. For small biotech companies, this moment also raises a critical question: how can we stay competitive with limited resources?
Inductive Bio Announces Publication of Successful Drug Optimization Collaboration with Nested Therapeutics
Inductive Bio, a leader in leveraging machine learning (ML) to accelerate compound optimization for small molecule drug discovery, announces the publication of the approach and findings from their recent collaboration with Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers.